

# Bu-Hai Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/665661/publications.pdf>

Version: 2024-02-01

12  
papers

738  
citations

1307594

7  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

886  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	1.6	159
2	The Effect of Hippocampal Avoidance Whole Brain Radiotherapy on the Preservation of Long-Term Neurocognitive Function in Non-Small Cell Lung Cancer Patients With Brain Metastasis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110342.	1.9	9
3	Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.	12.8	48
4	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-III A (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. <i>Lung Cancer</i> , 2020, 150, 164-171.	2.0	5
5	Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial. <i>Cancer Medicine</i> , 2020, 9, 6166-6172.	2.8	5
6	Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. <i>Oncology Letters</i> , 2019, 18, 3159-3169.	1.8	11
7	The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). <i>Journal of Thoracic Oncology</i> , 2019, 14, 503-512.	1.1	51
8	Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 14-14.	1.6	2
9	Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer: Results from one cohort of an ongoing phase 2 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11-11.	1.6	1
10	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-III A (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	10.7	436
11	Dosimetric study of different radiotherapy planning approaches for hippocampal avoidance whole-brain radiation therapy (HA-WBRT) based on fused CT and MRI imaging. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2015, 38, 767-775.	1.3	11
12	Construction the hairpin RNA recombinant plasmids targeting human Pokemon gene. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 730-733.	0.1	0